BGR GOVERNMENT AFFAIRS
Lobbying for NOVARTIS · Multinational biopharmaceutical company
-
ROBB WALTONPreviously held: Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes
-
REMY LEIGH BRIM MASONPreviously held: Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz
-
BRENT ALAN DEL MONTEPreviously held: See prior filing
-
JOHN STONEPreviously held: Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C
-
DANIEL FARMERPreviously held: Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space
-
JOEL D. BAILEYPreviously held: COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA, Sr. LA Rep. Baron Hill; Intern Rep. Rahall
-
RYAN LONGPreviously held: Senior Policy and Counsel, Speaker Kevin McCarthy; Senior Policy Advisor and Counsel, Minority Leader Kevin McCarthy; Deputy Staff Director and Staff Director, House Energy and Commerce Committee; LC, Rep Norwood; LA & LD, Rep Barton
-
CHRIS KELLY New on this filingPreviously held: Health Policy Dir., Leg. Asst., Leg. Corr., Front Office Coordinator, Staff Asst. Sen. Blackburn
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.